Rationale: Despite overwhelming evidence of the importance of brain renin-angiotensin system (RAS), the very existence of intrinsic brain RAS remains controversial.
E vidence demonstrates that the renin-angiotensin system (RAS) is intrinsic to the brain and has an integral role in the neural control of cardiovascular functions. 1, 2 Despite this, there is ongoing debate about the existence of an intrinsic brain RAS. 1, 3 Skeptics have argued that brain levels of renin are too low to have any impact on angiotensin II formation and hence its actions. [3] [4] [5] In addition, discrepancies in the cellular localization of angiotensinogen, angiotensin-converting enzyme, and angiotensin II type I receptors (AT 1 Rs) have made it difficult to explain the access of angiotensin II to cardiovascular-relevant neuronal circuits. 1 Discovery of (pro)renin receptor (PRR) may be a key to resolving this enigma.
PRR is a 350-aa transmembrane protein that binds prorenin or renin with comparable affinity. 6 PRR plays a dual role in the regulation of RAS activity: it binds prorenin/renin to facilitate angiotensin II formation locally; and the binding initiates an intracellular signaling cascade, which is similar to those associated with angiotensin II-mediated increases in pressor, proliferative, and fibrotic actions. 4, 6 These observations, coupled with recent data that PRR is highly expressed in cardiovascular-relevant brain regions and affects neurons in vitro, 7, 8 have led us to propose the following hypothesis: brain PRR is involved in the regulation of central cardiovascular function and its dysregulation may contribute to hypertension. Our objective in this study was to evaluate this hypothesis.
Six-week-old male Sprague-Dawley (SD) rats or SHRs were implanted with telemetry transducers into the abdominal aorta. Following 10 days recovery, animals were randomly divided into 2 groups. SD rats were used for bilateral injection into the supraoptic nucleus (SON) (A/P: 1.4 mm, D/V: 9.2 mm, M/L: 1.8 mm) with either adeno-associated virus (AAV)-human (h)PRR or control virus, AAV-green fluorescent protein (GFP); similarly, SHRs were injected with either AAV-PRR-short hairpin (sh)RNA or control virus, AAV-Sc-shRNA. Mean arterial pressure (MAP) and heart rate (HR) were monitored; plasma and urinary vasopressin (AVP) and gene transduction were assayed as described in the Online Methods section.
Results
First, we compared PRR mRNA levels in the brains of WKY rats and SHR because its expression is shown to be abundant in cardiovascular-relevant brain regions. 7 Compared with WKY rats, PRR mRNA levels were 70%, 45%, and 36% higher in the SON, the nucleus of the solitary tract, and the central amygdala, respectively ( Figure 1a ). Other brain regions tested did not show significant differences between these 2 strains of rats. PRR immunoreactivity was primarily localized in NeuN-positive cells (NeuN is a marker for neuronal nuclei); no significant staining of PRR was observed with glial fibrillary acidic protein (GFAP)-positive cells, an astroglial marker (Figure 1b and 1c ). Predominant neuronal localization of PRR is supported by our in vitro data. Neuronal cultures from WKY hypothalamus/brain stem regions showed a 2.7-fold higher PRR mRNA than comparable astroglial cultures. In addition, neuronal cultures from the SHRs had Ϸ2-fold greater PRR mRNA compared with WKY neurons (Online Figure I) .
Next, we studied the physiological role of PRR in the SON because this region exhibited the largest PRR expression difference between WKY rats and SHRs. We used AAV-hPRR to increase PRR in normotensive rats and AAV-PRR-shRNA to knockdown its expression in the SHRs. Bilateral microinjection of AAV-GFP showed a relatively restricted transduction of cells in the SON (Figure 2a ). Transduction with AAV-hPRR demonstrated an increase in hPRR mRNA without influencing the levels of endogenous rat PRR ( Figure  2b and 2c). Figure 3 shows that hPRR overexpression in the SON resulted in significant changes in the fluid homeostasis in SD rats. This increase was associated with a 21% decrease in daily water intake (PRR, 37.8Ϯ2 mL; GFP: 48.0Ϯ2.4 mL; PϽ0.05), 51% decrease in daily urine excretion (PRR, 9.7Ϯ1.8 mL; GFP, 19.7Ϯ2.4 mL; PϽ0.05), and 18% in- Figure II) . However, PRR overexpression in the SON had no effect on MAP and HR (Online Figure III) .
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We constructed a shRNA-targeted PRR, which was cloned into the AAV vector. Infection of neuronal cultures with this PRR-shRNA caused Ϸ60% decreases in both PRR mRNA and renin stimulation of extracellular signal-regulated kinase (ERK)1/2 phosphorylation (Online Figure IV) . Transduction of SHR SON with PRR-shRNA attenuated the age-dependent increases in MAP (⌬MAP) and caused a decrease in HR (⌬HR) compared with baseline MAP (PRR-shRNA, 124.6Ϯ7.6 mm Hg; Sc-shRNA: 121.2Ϯ3.0 mm Hg) and HR (PRR-shRNA, 400.5.Ϯ5.1 bpm; Sc-shRNA, 388.6Ϯ5.9 bpm). Eight weeks following microinjection, ⌬MAP was 22.4Ϯ3.9 mm Hg in PRR-shRNA rats compared with 46.0Ϯ6.2 mm Hg in Sc-shRNA animals. Similarly, ⌬HR was decreased in shRNAtreated SHRs (PRR-shRNA, Ϫ81.1Ϯ9.0 bpm; Sc-shRNA: Ϫ51.2Ϯ6.9 bpm; PϽ0.05) (Figure 4a ). These changes were associated with a 38% decrease in PRR mRNA in the SON (Figure 4b ). In addition, plasma AVP was decreased by 34% in PRR-shRNA animals (PRR-shRNA, 16.3Ϯ2.4 pg/mL; Sc-shRNA, 24.0Ϯ2.3 pg/mL; PϽ0.05) (Figure 4b ). In contrast, transduction of WKY SON with PRR-shRNA failed to exert any effect on MAP (PRR-shRNA, 104.5Ϯ2.6 mm Hg; PRR-scRNA, 105.1Ϯ9.0 mm Hg; nϭ6 for each group).
Finally, we determined the cellular effects of prorenin and renin in neuronal cultures. A dose-and-time-dependent increase in angiotensin I and II formation was observed when the cultures were incubated with human prorenin and angiotensinogen (Online Figure V) . Furthermore, incubation of neuronal cultures with renin in the presence of losartan, an AT 1 R blocker, resulted in a rapid and transient increase in phosphorylated ERK1/2 in both strains of rats although this stimulation was 2-fold greater in the SHR neurons (Online Figure VI ).
Discussion
Our study is significant in a number of ways. (1) It demonstrates that PRR in the brain is physiologically relevant because its overexpression in the SON stimulates AVP secretion and alters fluid balance in normal rats. In addition, chronic knockdown of PRR causes a significant attenuation of MAP and HR in SHRs. Thus, PRR may play a crucial role in the neuronal control of cardiovascular function by possibly regulating AVP secretion. (2) PRR mediates the generation of angiotensin II and stimulates intracellular signaling, similar to its action in the periphery. 3, 6 Therefore, its presence further strengthens the presence of a functional intrinsic brain RAS.
(3) Most previous studies implicate functions of PRR in pathophysiological states, such as cardiovascular disease and diabetes, or from in vitro situations. 6, 9 Our study provides data of functional PRR in a normotensive animal and demonstrates a beneficial outcome of PRR in hypertension by its chronic knockdown. Finally, our data demonstrate the role of SON in blood pressure control in the SHR model of hypertension.
PRR expression is widespread in brain cardioregulatory regions, consistent with the recent report of Contrepas et al. 7 However, our study is novel in that it shows that expression levels of PRR are higher in the SON of SHR compared with WKY controls. This increase appears to be genetically linked because it is maintained in primary neuronal cultures of prehypertensive SHR. It is pertinent to point out that these cultures closely mimic the changes observed in the RAS activity of adult SHR. 1 PRRs are primarily localized on neuronal cells because PRR-positive cells costain with NeuNpositive cells Furthermore, GFAP-positive cells exhibit little PRR staining. This conclusion is further supported by our observation that PRR levels are several-fold lower in astroglial cultures than in neuronal cultures from the brains of both WKY rats and SHR.
Increased expression of PRR in the SHR SON appears to exert pathophysiological influences, a conclusion supported by our knockdown data. Long-term knockdown of PRR is associated with attenuation of hypertension development and a decrease in plasma AVP. Consistent with these data is our observation that overexpression of PRR in the SON of normotensive rat results in an increase in plasma and urinary AVP. However, increases in plasma AVP levels were not associated with an increase in MAP. There may be a number of explanations for this unexpected result. (1) Increases in plasma AVP observed in this study were insufficient to affect MAP. (2) Redundant physiological mechanisms in normal rats may be able to overcome increases in plasma AVP, a view consistent with the present dogma that AVP appears to exert little effect on MAP in normal individuals and animals.
(3) Circadian rhythmic release of AVP from the SON (rather than a continual increased secretion) is important in its cardiovascular effects. 10 Transgenic overexpression of hPRR may not maintain this pattern of release, and (4) PRR may inhibit sympathetic nervous system activity in normal rats, thus counteracting potentially hypertensive effects of circulating AVP.
Finally, our data show that the neuronal PRR has dual functions. First, by binding to renin/prorenin, it increases the generation of angiotensin II. This solid-phase enzyme catalysis could provide thousands-fold higher rates of angiotensin formation than liquid phase occurring in the plasma. Thus, even a small amount of renin/prorenin would be capable of generating physiologically relevant concentrations of angiotensin II locally in the brain. We propose that this catalysis occurs on the surface of AT 1 R-expressing neurons. Evidence in support of this view are: (1) key components of angiotensin II actions, such as angiotensin-converting enzyme and AT 1 R, are present in the neurons 1, 3 ; and (2) our preliminary data have shown that PRR and AT 1 R are colocalized on the SON neurons (data not shown). Second, binding of renin/PRR initiates signaling involving ERK1/2. These kinases have been shown to be involved in the regulation of neuronal activity. 1 This signaling would complement AT 1 R mediated neuromodulation.
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